Pursuant to Reg 30 of SEBI LODR Regulations, the Board has, at its meeting held today, inter-alia, considered and approved the following:- The Scheme of Arrangement for demerger of real estate business of the Company comprising of Radhika Heights Limited alongwith its subsidiaries and two properties, into its wholly owned subsidiary namely, Ravinder Heights Limited, subject to applicable approvals. In continuation to our earlier communications dated May 30, 2019 and May 31, 2019, we would like to inform you that BSE Limited and National Stock Exchange of India Limited have issued letters dated September 19, 2019 and September 20, 2019 respectively with no adverse observations on our application filed under Regulation 37 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the draft Scheme of Arrangement between Panacea Biotec Limited and Ravinder Heights Limited and their respective shareholders and creditors pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, subject to approval of National Company Law Tribunal (NCLT). A copy each of the above said Observation Letters is enclosed herewith for reference. The said Observation Letters are also available on the website of the Company and can be accessed at https://www.panaceabiotec.com/scheme-of-arrangement. (As Per BSE Announcement Dated on 21/09/2019) In continuation to our earlier communications dated May 30, 2019, May 31, 2019 and September 21, 2019 with respect to proposed Scheme of Arrangement between Panacea Biotec Limited and Ravinder Heights Limited and their respective shareholders and creditors pursuant to sections 230 to 232 & section 66 and other applicable provisions of the Companies Act, 2013, we would like to inform you that the Company along with Ravinder Heights Limited has filed joint first motion application for approval of the said Scheme of Arrangement before the Hon'ble National Company Law Tribunal, Chandigarh Bench ('NCLT') on Friday, i.e., September 27, 2019 to seek requisite directions. The aforesaid matter was listed before the Hon'ble NCLT on Friday, October 04, 2019. The Hon'ble NCLT heard the matter and has adjourned the same for further consideration on October 18, 2019. This is for your information and record. (As Per BSE Announcement Dated 05.10.2019) Please find enclosed proceedings of NCLT convened meetings of equity shareholders and unsecured creditors of Panacea Biotec Limited held on Tuesday, January 28, 2020 at 11:00 a.m. and 2:00 p.m. respectively. (As Per BSE Announcement dated on 29/01/2020) This is in continuation to our earlier letter dated 29.01.2020 intimating the proceedings of the NCLT convened meeting of equity shareholders of Panacea Biotec Limited ('Demerged Company') held on Tuesday, 28.01.2020, as required under Reg 44 of the SEBI LODR Regulations. We are now submitting the detailed results of remote e-voting and poll conducted at the said meeting. The Demerged Company has provided voting facility through (i) remote e-voting; and (ii) by way of poll through ballot papers at the venue of the meeting to its equity shareholders. Pursuant to Regulation 44(3) of the SEBI LODR Regulations read with amended Rule 20 of Companies (Management and Administration) Rules, 2015, the combined results of remote e-voting and poll conducted in respect of voting by the equity shareholders of Demerged Company along with the Scrutinizer's Report is enclosed herewith as Annexure - A. (As Per BSE Announcement Dated 30.01.2020) Trading Members of the Exchange are hereby informed that, pursuant to the Scheme of Arrangement (for Demerger) approved by the Hon'ble National Company Law Tribunal, Chandigarh Bench (NCLT), Panacea Biotec Limited has fixed the Record Date for the purpose of determining entitlement of the shareholders of the Company, as per details given below: COMPANY NAME CODE Panacea Biotec Limited (531349) RECORD DATE 22.09.2020 PURPOSE As per Scheme of Arrangement sanctioned by the Hon'ble National Company Law Tribunal, Chandigarh Bench (NCLT), between, Panacea Biotec Limited (Demerged Company) and Ravinder Heights Limited (Resulting Company) and Their Respective Shareholders and Creditors: - Upon coming into effect of the aforesaid Scheme and in consideration of transfer of the Real Estate Business of Panacea Biotec Limited Into Ravinder Heights Limited; Ravinder Heights Limited shall issue and allot Equity Shares to the shareholders of Panacea Biotec Limited. in the following proportion: '1 fully paid up equity share of Re. 1/- each fully paid up of Ravinder Heights Limited shall be issued and allotted for every 1 fully paid up equity share of Re. 1/- each fully paid up held in Panacea Biotec Limited.' EX-ENTITLEMENT FROM DATE & SETT. NO. 21/09/2020 DR-120/2020-2021 Note: Pursuant to SEBI Circular No. SEBI/Cir/ISD/1/2010 dated November 2, 2010, Trading members are hereby informed that the trading in the equity shares of the aforesaid company shall be transferred from B' group to T' group (Trade for Trade settlement) w.e.f. September 21, 2020 and pursuant to SEBI Circular No. CIR/MRD/DP/01/2012 dated January 20, 2012; the aforesaid scrip shall be a part of Call Auction in Pre-open Session on September 21, 2020. Subject to compliance with requisite formalities, the shares of Resulting company i.e. Ravinder Heights Limited will be listed on BSE Limited. (As Per BSE Notice Dated on 17.09.2020)